Intensity Therapeutics Q3 2026 net loss widens 33% to $3.54 million

Bitget2026/11/05 12:46

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Intensity Therapeutics’ third-quarter 2026 net loss widened 33% year over year to $3.54 million.
Research and development expenses rose 56% to $2.43 million, primarily due to higher INVINCIBLE-3 study costs.
Cash and cash equivalents totaled $8.49 million at September 30, 2026.
Patient enrollment activities resumed in both the Phase 3 sarcoma and Phase 2 triple-negative breast cancer studies during the third quarter.
The breast cancer study targets enrollment completion by end-2027, with an independent safety review update planned for the first quarter of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intensity Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611050745PR_NEWS_USPR_____NE89211) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Intensity Therapeutics Q3 2026 net loss widens 33% to $3.54 million

You may also like

Crypto prices